The proposed study will examine the feasibility, acceptability, safety, effectiveness, and cost of an Accessible Care intervention for engaging people who inject illicit drugs (PWID) in hepatitis C care. Accessible Care for PWID is low-threshold care provided in programs designed specifically for PWID where they can comfortably access care without fear of shame or stigma. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator (HCCC), on-site at a collaborating needle exchange program. The proposed study will compare the effectiveness of Accessible Care with Usual Care (referrals to existing services) in facilitating linkage, engagement, and retention of PWID in care for hepatitis C, addiction, and HIV prevention. The primary outcome is sustained virologic response, which constitutes virologic cure. Substance use and HIV and HCV risk behaviors are secondary outcomes.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Proportion of Patients to Achieve SVR12 at 1 Year
Timeframe: each participant will be assessed at 1 year post entry
Proportion of Patients in Each Arm Referred to Hepatitis C Treatment Provider
Timeframe: each participant will be assessed at 1 year post entry
The Proportion of Participants With Hepatitis C Treatment Engagement by 12 Months That Attended an Initial Visit
Timeframe: end of study (12 months)
Proportion of Patients in Each Arm Who Complete a Medical Evaluation for Antiviral Treatment
Timeframe: each participant will be assessed at 1 year post entry
Proportion of Participants in Each Arm Who Initiated Treatment
Timeframe: Each participant will be assessed 1 year post entry